Chemours Co (CC): debt financing — Chemours amends credit agreement to replace LIBOR with SOFR benchmark

Chemours Co

Entered Amendment No. 2 on March 10, 2023, transitioning from LIBOR to SOFR.
Revolving Credit Facility remains $800 million; term loan facility unchanged.
No changes to other material terms of the existing credit agreement.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Chemours Co amended credit facility with JPMorgan Chase Bank, N.A. at replaces the interest rate benchmark from the London Interbank Offered Rate (“LI.

Instrument: credit facility
Counterparty: JPMorgan Chase Bank, N.A.
Rate: replaces the interest rate benchmark from the London Interbank Offered Rate (“LI
Event: amendment

Exact text from the filing

Amendment No. 2 replaces the interest rate benchmark from the London Interbank Offered Rate (“LIBOR”) to the Secured Overnight Financing Rate (“SOFR”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Chemours Co amended Amendment No. 2 with JPMorgan Chase Bank, N.A. (effective 2023-03-10).

Action: amendment
Agreement: credit facility
Counterparty: JPMorgan Chase Bank, N.A.
Effective: 2023-03-10

Exact text from the filing

On March 10, 2023, The Chemours Company (the “Company”) entered into Amendment No. 2 (“Amendment No. 2”) to the Amended and Restated Credit Agreement, dated as of April 3, 2018, as amended on October 7, 2021, by and among the Company, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent (the “Credit Agreement”).

View on SEC.gov

8 debt financings filed in the last 30 days. Browse all debt financings →

Chemours Co filing history →

Source: SEC EDGAR

accession 0000950170-23-008143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.